Transseptal Solutions

Company Overview

Snapshot

Founded in November 2013, Transseptal Solutions operates with 1–10 employees. The company has developed an integrated transseptal system, the TSP Crosser, which received FDA clearance in October 2018.

Business overview

Transseptal Solutions develops medical devices for improving left-atrium-access procedures, addressing the expanding indications for left-heart treatments. Its core product, the CE-marked and FDA-approved TSP Crosser, is an integrated transseptal system designed for precise engagement of the fossa ovalis and steerable sheath navigation. The system facilitates various left-side procedures, including transcatheter mitral repair/replacement, PVL closure, atrial fibrillation ablation, and left-atrial appendage occlusion, serving the cardiology and medical technologies sectors.

Strategic signal

In June 2019, Transseptal Solutions announced the first clinical use of its TSP Crosser in the United States. This milestone validated the device's practical application in a key market, signaling its readiness for broader adoption in left-atrium access procedures and demonstrating the company's progress in commercializing its medical technology.

Company Intelligence Q&A

What is Transseptal Solutions' primary product?

Transseptal Solutions' primary product is the TSP Crosser, an integrated transseptal system designed for precise transseptal puncture and left atrium navigation.

When did the TSP Crosser receive FDA clearance?

The TSP Crosser transseptal access device received FDA clearance in October 2018.

When was the first clinical use of the TSP Crosser in the United States?

Transseptal Solutions announced the first clinical use of its TSP Crosser in the United States in June 2019.

What procedures does the TSP Crosser facilitate?

After puncture, the steerable sheath of the TSP Crosser serves as a guiding catheter for left-side procedures, including transcatheter mitral repair/replacement, PVL closure, atrial fibrillation ablation, and left-atrial appendage occlusion.

What is the company's focus in medical technology?

Transseptal Solutions focuses on developing a novel approach to transseptal puncture and left atrium navigation, aiming to improve left-atrium-access procedures and support expanding indications for left-heart treatments.